Impact of High Doses of Vitamin D on Specific Metabolic Parameters in Type 2 Diabetes Patients: A Prospective Biomedical Study.

High-dose vitamin D supplementation produced a significantly greater increase in 25(OH)D levels compared to lower-dose supplementation.

• Group A (10,000 IU/day) showed a median increase in 25(OH)D of +13.3 ng/mL (from 17.2 to 31.8 ng/mL)
• Group B (960 IU/day) showed a median increase in 25(OH)D of +8.1 ng/mL (from 18.5 to 28.2 ng/mL)
• The difference between groups was statistically significant (p = 0.015)
• Study duration was 12 weeks with 30 patients enrolled

PTH decreased in the high-dose vitamin D group over the 12-week supplementation period.

• In Group A (10,000 IU/day), PTH decreased from a median of 3.27 to 2.76 pmol/L
• The median change in PTH in the high-dose group was -0.27 pmol/L
• Patients with larger increases in 25(OH)D tended to show greater reductions in PTH

A strong, statistically significant negative correlation was observed between changes in 25(OH)D and changes in PTH.

• Spearman r = -0.69052, p = 0.0044
• This correlation was observed across the full study sample
• The finding indicates that as 25(OH)D concentrations increased, PTH concentrations decreased

Other metabolic markers including HbA1c, fasting blood glucose, calcium, and phosphorus remained stable over the 12-week study period.

• No significant changes were observed in HbA1c or fasting blood glucose (FBG) in either group
• Calcium and phosphorus levels also remained stable
• These parameters were among the primary endpoints of the study
• The stability of these markers was observed in T2DM patients with low baseline 25(OH)D concentrations

The study design assigned patients to high-dose or lower-dose vitamin D based on recruitment order using odd/even identification numbers.

• Group A received 10,000 IU/day of cholecalciferol; Group B received 960 IU/day
• Thirty adult patients with T2DM and low serum 25(OH)D concentrations were enrolled
• The study was a prospective observational biomedical study lasting 12 weeks
• Assignment was based on odd/even identification numbers rather than randomization

High-dose vitamin D supplementation was considered effective and safe for correcting vitamin D deficiency in T2DM patients.

• The high-dose group achieved a median 25(OH)D level of 31.8 ng/mL from a deficient baseline of 17.2 ng/mL
• No adverse metabolic effects were noted, including no significant changes in calcium levels
• Authors concluded findings 'support the effectiveness and safety of high-dose vitamin D supplementation in correcting vitamin D deficiency and reducing PTH levels in patients with T2DM'
• The authors noted the need for longer-term studies to evaluate broader metabolic effects